India's Biosimilars Revolution

The increasing incidence of chronic illnesses such as cancer, diabetes, and autoimmune disorders, which necessitate long-term biologic therapies, is driving the growth of the biosimilar market in India.

- Ayesha Siddiqui

Since introducing the "Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India" in 2012, which was later revised in 2016, the Indian biosimilar industry has made significant strides. With a robust pharmaceutical sector, India is now a leader in biosimilar production, boasting approximately 100 domestically approved biosimilars. Several Indian companies have also received approval for Biosimilars in the US and Europe. Indian companies have catered to the local market and emerged as global frontrunners in biosimilars, playing a crucial role in enhancing the accessibility of biological therapies. Biosimilars are notably impacting various therapeutic areas in India, particularly in oncology, autoimmune disorders, and diabetes. In the oncology sector, biosimilars such as Trastuzumab, Bevacizumab, Rituximab, and Cetuximab are effectively treating a substantial patient population across multiple cancer types. Additionally, there is a robust pipeline of biosimilars in the oncology field. For Rheumatoid Arthritis, biosimilars for Etanercept and Adalimumab have been approved, expanding treatment options for many patients. The introduction of biosimilar insulins in the Indian healthcare landscape is crucial for improving access to insulin for all diabetes patients. The growing availability of insulin biosimilars is expected to enhance accessibility and potentially reduce costs for individuals with diabetes. Furthermore, several other biosimilars have been approved for conditions such as neutropenia, anemia, and multiple sclerosis. These cost-effective alternatives significantly improve access to vital biologic therapies for patients nationwide.

• Oncology: Trastuzumab, rituximab, and later, bevacizumab.

• Autoimmune Diseases: TNF inhibitors like etanercept and adalimumab.

• Haematology: Filgrastim, epoetin for anaemia and neutropenia.